Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin’s Lymphoma
Lymphoma
-
-
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Relapsed Non-Hodgkin’s Lymphoma
-
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
-
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
-
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin’s Lymphoma
-
Rituximab and Cladribine in Treating Patients With Newly Diagnosed Non-Hodgkin’s Lymphoma
-
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
-
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Categories
Alliance Committee
Browse by Year